Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease
Status: | Withdrawn |
---|---|
Conditions: | Parkinsons Disease |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 21 - Any |
Updated: | 11/4/2018 |
Start Date: | March 2009 |
End Date: | June 2011 |
Comparison of Continuous and Pulsatile Apomorphine Administration in Parkinson's Disease Complicated by Levodopa-induced Dyskinesia
The purpose of this study is to compare the effects of apomorphine, given by two different
methods, to determine how best to manage dyskinesias.
methods, to determine how best to manage dyskinesias.
Levodopa is a drug that can be taken by mouth, and improves the symptoms of Parkinson's
disease (PD). However it can eventually cause involuntary movements called dyskinesia and
motor fluctuations—fluctuations in the control of symptoms, often referred to as "off" and
"on." Apomorphine is a drug that works as well as levodopa, but does not work if taken by
mouth.
The purpose of this study is to compare the effects of apomorphine in people with PD who have
levodopa-induced motor fluctuations and dyskinesias. In the trial, researchers will compare
the effects of apomorphine administered by subcutaneous bolus injections (pulsatile) and by
ambulatory infusion pumps (continuous) in 24 people with PD, for 6 months.
After an initial screening, potential participants will undergo a test to verify that they
can tolerate and respond to apomorphine. Those who meet all of the requirements will be
randomized to receive the study drug via injections (shots) using an injector pen or a
portable infusion pump. Apomorphine will be given either continuously using the portable pump
during the waking day or intermittently by injection, for 6 months. The pump will be carried
on a belt and connected by a tube to a small needle under the skin. Injections of apomorphine
under the skin will be self-administered by the participants or administered by friends or
family members using injector pens.
After 6 months, the effects of apomorphine use will be assessed by measuring how the
participants respond to levodopa and by measuring their symptoms during the course of the
study. Participants will be followed initially every week, then biweekly, and then monthly in
an outpatient clinic for 6 months. During this time, they may receive adjustments of
apomorphine doses as well as doses of other antiparkinson medications.
disease (PD). However it can eventually cause involuntary movements called dyskinesia and
motor fluctuations—fluctuations in the control of symptoms, often referred to as "off" and
"on." Apomorphine is a drug that works as well as levodopa, but does not work if taken by
mouth.
The purpose of this study is to compare the effects of apomorphine in people with PD who have
levodopa-induced motor fluctuations and dyskinesias. In the trial, researchers will compare
the effects of apomorphine administered by subcutaneous bolus injections (pulsatile) and by
ambulatory infusion pumps (continuous) in 24 people with PD, for 6 months.
After an initial screening, potential participants will undergo a test to verify that they
can tolerate and respond to apomorphine. Those who meet all of the requirements will be
randomized to receive the study drug via injections (shots) using an injector pen or a
portable infusion pump. Apomorphine will be given either continuously using the portable pump
during the waking day or intermittently by injection, for 6 months. The pump will be carried
on a belt and connected by a tube to a small needle under the skin. Injections of apomorphine
under the skin will be self-administered by the participants or administered by friends or
family members using injector pens.
After 6 months, the effects of apomorphine use will be assessed by measuring how the
participants respond to levodopa and by measuring their symptoms during the course of the
study. Participants will be followed initially every week, then biweekly, and then monthly in
an outpatient clinic for 6 months. During this time, they may receive adjustments of
apomorphine doses as well as doses of other antiparkinson medications.
Inclusion Criteria:
- idiopathic Parkinson's Disease
- clear response to levodopa (sinemet)
- "off" at least 20% of waking day
- dyskinesias present for at least two hours of waking day
- subject or caregiver able to master use of drug delivery system (injector pen or pump)
Exclusion Criteria:
- physical complications that would preclude safe participation
- standing systolic BP of <80
- lack of tolerance or response to apomorphine
- drug/alcohol abuse
We found this trial at
1
site
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311

Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
